NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $7.27 -0.02 (-0.29%) As of 01:08 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SELLAS Life Sciences Group Stock (NASDAQ:SLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SLS alerts:Sign Up Key Stats Today's Range$6.85▼$7.5050-Day Range$4.01▼$7.4252-Week Range$1.39▼$7.80Volume3.97 million shsAverage Volume7.60 million shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells. The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1. GPS is currently being evaluated in ongoing Phase II/III clinical trials for acute myeloid leukemia (AML), malignant pleural mesothelioma and ovarian cancer. SELLAS is also exploring combination regimens of GPS with immune checkpoint inhibitors to enhance antitumor activity, as well as next-generation cellular approaches intended to broaden its therapeutic platform beyond peptide vaccines. SELLAS conducts its clinical trials across multiple geographies, including North America, Europe and Japan, leveraging collaborations with leading academic research centers and contract research organizations. These partnerships enable the company to advance its programs efficiently through regulatory pathways and to access patient populations in key oncology indications. The management team at SELLAS brings together seasoned executives and scientific leaders with extensive experience in oncology drug development. The company remains committed to translating its WT1-targeted immunotherapy approach into new treatment options for patients with high-unmet-need cancers.AI Generated. May Contain Errors. Read More SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 33% of companies evaluated by MarketBeat, and ranked 745th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialSELLAS Life Sciences Group has a consensus price target of $10.00, representing about 37.6% upside from its current price of $7.27.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 2 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -31.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -31.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 15.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.34% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 11.68, which indicates bearish sentiment.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 0.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.89 News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for SELLAS Life Sciences Group this week, compared to 2 articles on an average week.Search Interest43 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by Insiders1.20% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by Institutions17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLS Stock News HeadlinesSELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?May 16 at 8:15 AM | uk.finance.yahoo.comSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readoutMay 14, 2026 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 19 at 1:00 AM | Profits Run (Ad)SELLAS Life Sciences to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13, 2026 | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13, 2026 | seekingalpha.comSELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline ProgressesMay 13, 2026 | benzinga.comSELLAS Life Sciences surges on earnings beat, trial updateMay 12, 2026 | investing.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $3.77 on January 1st, 2026. Since then, SLS stock has increased by 92.8% and is now trading at $7.2690. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group shares reverse split on Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's top institutional investors include Dagco Inc. (0.57%), Bank of America Corp DE (0.34%), Bank of New York Mellon Corp (0.26%) and Quantinno Capital Management LP (0.04%). Insiders that own company stock include Katherine Bach Kalin, Jane Wasman and Nostrand Robert L Van. View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings5/12/2026Today5/19/2026Stifel 2026 Targeted Oncology Virtual Forum5/19/2026A.G.P.'s Annual Virtual Healthcare Conference5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SLS's financial health is in the Green zone, according to TradeSmith. SLS has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year Founded2006Price Target and Rating Average Price Target for SELLAS Life Sciences Group$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+38.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.12% Return on Assets-42.63% Debt Debt-to-Equity RatioN/A Current Ratio17.22 Quick Ratio17.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book15.74Miscellaneous Outstanding Shares186,030,000Free Float183,801,000Market Cap$1.35 billion OptionableNot Optionable Beta2.24 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SLS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
